Literature DB >> 10986677

Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women.

E A Joura1, A Lösch, M G Haider-Angeler, G Breitenecker, S Leodolter.   

Abstract

OBJECTIVE: To determine trends in the epidemiology of vulvar intraepithelial neoplasia (VIN) and squamous cell carcinoma (SCC) of the vulva in a Central European sample during the last decade. STUDY
DESIGN: A total of 366 women with VIN 2 and 3 (n = 128) or vulvar SCC (n = 238) presented within two four-year periods separated by one decade (1985-1988 and 1994-1997). We performed a retrospective analysis of the clinicopathologic records of the cohorts.
RESULTS: The number of women with high grade VIN (n = 29 vs. 99) tripled during the last decade, while the incidence of vulvar SCC remained stable. In women < or = 50 years old, the incidence of high grade VIN increased by 392% (n = 12 vs. 59) and of invasive vulvar cancer by 157% (n = 7 vs. 18). In the earlier cohort there were 7/126 (5%) women with invasive vulvar SCC under the age of 50 and, in the latter cohort, 18/112 (16%, P < .01).
CONCLUSION: Over the past decade a striking increase occurred in the incidence of VIN and an increase in invasive vulvar SCC in young women.

Entities:  

Mesh:

Year:  2000        PMID: 10986677

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  41 in total

Review 1.  Medical interventions for high grade vulval intraepithelial neoplasia.

Authors:  Litha Pepas; Sonali Kaushik; Andrew Bryant; Andy Nordin; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients.

Authors:  Kruti P Maniar; Brigitte M Ronnett; Russell Vang; Anna Yemelyanova
Journal:  Am J Surg Pathol       Date:  2013-01       Impact factor: 6.394

3.  Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions.

Authors:  Donata Grimm; Christine Eulenburg; Oliver Brummer; Anna-Katharina Schliedermann; Fabian Trillsch; Katharina Prieske; Friederike Gieseking; Enzia Selka; Sven Mahner; Linn Woelber
Journal:  Support Care Cancer       Date:  2015-06-23       Impact factor: 3.603

4.  Vulvar Intraepithelial Neoplasia 3 in Women Less Than 35 Years.

Authors:  Joshua P Kesterson; Shashikant Lele
Journal:  J Low Genit Tract Dis       Date:  2009-10       Impact factor: 1.925

5.  High-resolution genomic profiling of human papillomavirus-associated vulval neoplasia.

Authors:  K J Purdie; C A Harwood; K Gibbon; T Chaplin; B D Young; J B Cazier; N Singh; I M Leigh; C M Proby
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

6.  Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence.

Authors:  J J Wallbillich; H E Rhodes; A M Milbourne; M F Munsell; M Frumovitz; J Brown; C L Trimble; K M Schmeler
Journal:  Gynecol Oncol       Date:  2012-08-04       Impact factor: 5.482

Review 7.  Surgical interventions for high-grade vulval intraepithelial neoplasia.

Authors:  Sonali Kaushik; Litha Pepas; Andy Nordin; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2014-03-04

8.  Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.

Authors:  Lucia Six; Sepp Leodolter; Heather L Sings; Eliav Barr; Richard Haupt; Elmar A Joura
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 9.  Squamous precursor lesions of the vulva: current classification and diagnostic challenges.

Authors:  Lien N Hoang; Kay J Park; Robert A Soslow; Rajmohan Murali
Journal:  Pathology       Date:  2016-04-23       Impact factor: 5.306

10.  Therapy for Primary Vulvar Carcinoma.

Authors:  D Herr; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.